Skip to content

Somatic Symptom Disorders in Patients With Myocardial Bridge

EARLY Assessment of Somatic Symptom Disorder in Patients With MYOcardial Bridge by Somatic Symptom Scale China (SSS-CN) (EARLY-MYO-SSS-CN-Ⅱ)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04664387
Enrollment
1357
Registered
2020-12-11
Start date
2016-10-30
Completion date
2020-05-08
Last updated
2022-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Bridge, Somatic Symptom Disorder

Keywords

myocardial bridge, somatic symptom disorder, SSS-CN

Brief summary

The purpose of this study was to investigate the prevalence of physical and mental disorder in the population of patients with myocardial bridge and to describe the relationship between clinical features and the occurrence of somatic disorder.

Detailed description

Myocardial bridge (MB), a congenital cardiac anomaly, is an unignored contribution to chest pain. Patients with MB often complain about chest discomfort more serious than the degree of vessel compression. The symptoms are also often inconsistence with the degree of coronary stenosis. Reports suggested that patients with MB may companioned with depression and anxiety. Moreover, patients with MB often have other systemic complaints including stomach pain, pain on the back, ear blockage, et al. Investigators assume that somatic symptom disorder (SSD) may play a part in aggregating the severity of symptoms. In order to screen SSD, investigators previously developed the Somatic Symptom Scale-China (SSS-CN) questionnaire. It is a somatic and psychological symptom scale which was developed based on the DSM-5 to assess a combination of psychological, behavioral and somatic symptoms. It is designed to assess the presence and severity of the symptoms. Investigators have validated its reliability and validity in a previous study. The purpose of this study was to investigate the prevalence of physical and mental disorder in the population of patients with MB and to describe the relationship between clinical features and the occurrence of somatic disorder.

Interventions

DIAGNOSTIC_TESTcoronary angiography

A coronary angiography is a test to find out if there is stenosis in coronary artery.

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* cardiology inpatients with the age older than 18, complained with chest discomfort and was suspected with coronary artery disease. * undertook Somatic Symptom Scale-China (SSS-CN) questionnaire, Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) questionnaires. * underwent cardiac angiography. * agree to participate.

Exclusion criteria

* patients who are in emergency or unconsciousness. * patients who refuse to participate or with unfinished questionnaire. * the questionnaires were undertook after the angiography. * patients who have previously been confirmed to have mental disorders, mental retardation or dementia, cannot finish questionnaires * patients who currently take anti-anxiety or anti-depression agents. * patients who have been confirmed to have heart diseases other than coronary vascular disease. * patients who have been previously confirmed to have other physical diseases.

Design outcomes

Primary

MeasureTime frameDescription
the score of Somatic Symptom Scale-China (SSS-CN)within 24 hours before the coronary angiography.to compare the score of Somatic Symptom Scale-China questionnaire between patients with and without myocardial bridge. SSS-CN is a self-administered questionnaire with 20 items and scoring 1, 2, 3, 4 to each item. The total score is from 20 to 80. The higher the score is, the higher frequency that the symptoms presented.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026